Next Article in Journal
Enhanced Sensing Performance of Integrated Gas Sensor Devices
Previous Article in Journal
Thermoelectric Microsensor Based on Ultrathin Si Films
 
 
Proceeding Paper

Anti-Cancer Acitivity of Etodolac and Its Derivatives on Prostate and Colorectal Cancer Cell Lines †

1
School of Medicine, Department of Biophysics, Maltepe, Marmara University, 34854 Istanbul, Turkey
2
School of Pharmacy, Department of Pharmaceutical Chemistry, Marmara University, Haydarpasa, 34668 Istanbul, Turkey
*
Author to whom correspondence should be addressed.
Presented at the 2nd International Cell Death Research Congress, Izmir, Turkey, 1–4 November 2018.
Proceedings 2018, 2(25), 1573; https://doi.org/10.3390/proceedings2251573
Published: 7 December 2018
(This article belongs to the Proceedings of The 2nd International Cell Death Research Congress)
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used as anti-inflammatory and analgesic agents. This family of drugs suppresses prostaglandin synthesis through inhibition of cyclooxygenase (COX) enzymes. Recent studies showed that anti-carcinogenic effects of these drugs are especially mediated by COX-2 enzyme. Etodolac is a COX-2 inhibitor and though not perfectly selective, it exhibits “preferential selectivity” for COX-2. In this study, the anti-proliferative and apoptotic effects of etodolac and its hydrazone or triazole derivatives (SGK 206 and SGK 242, respectively), were investigated on prostate cancer cell line PC-3 and human colorectal carcinoma cell line HT-29. Our data showed that SGK 206 and SGK 242 were more effective in the inhibition of proliferation and induction of apoptosis compared to etodolac in both cell lines.
Keywords: PC-3; HT-29; etodolac; cancer; apoptosis PC-3; HT-29; etodolac; cancer; apoptosis
MDPI and ACS Style

Sevinç, S.K.; Orun, O.; Tiber, P.M.; Çıkla-Süzgün, P.; Küçükgüzel, Ş.G. Anti-Cancer Acitivity of Etodolac and Its Derivatives on Prostate and Colorectal Cancer Cell Lines. Proceedings 2018, 2, 1573. https://doi.org/10.3390/proceedings2251573

AMA Style

Sevinç SK, Orun O, Tiber PM, Çıkla-Süzgün P, Küçükgüzel ŞG. Anti-Cancer Acitivity of Etodolac and Its Derivatives on Prostate and Colorectal Cancer Cell Lines. Proceedings. 2018; 2(25):1573. https://doi.org/10.3390/proceedings2251573

Chicago/Turabian Style

Sevinç, Sevgi Koçyiğit, Oya Orun, Pınar Mega Tiber, Pelin Çıkla-Süzgün, and Ş. Güniz Küçükgüzel. 2018. "Anti-Cancer Acitivity of Etodolac and Its Derivatives on Prostate and Colorectal Cancer Cell Lines" Proceedings 2, no. 25: 1573. https://doi.org/10.3390/proceedings2251573

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop